#PVLA↓

PVLA/ 02/24/2026 · 8:45 AM

Palvella Soars After Positive Phase 3 Data – First Approved Therapy for Microcystic LMs in Sight

Palvella Therapeutics shares surged 30% after strong Phase 3 SELVA trial data for QTORIN rapamycin gel in microcystic lymphatic malformations. First potential FDA-approved treatment could arrive in 2027.

PVLA/ 12/16/2025 · 12:00 PM

FDA Grants Fast Track Status to New Skin Condition Treatment

Palvella Therapeutics (PVLA) receives FDA Fast Track designation for QTORIN rapamycin gel to treat angiokeratomas, a rare skin condition with no approved therapies affecting 50,000+ US patients.

PVLA/ 11/19/2025 · 3:29 PM

Raymond James Boosts Palvella Therapeutics to Strong Buy Ahead of Key Phase 2 Data

Raymond James upgrades Palvella Therapeutics to Strong Buy with a new $143 price target, citing strong confidence in upcoming Phase 2 TOIVA readout for QTORIN rapamycin.